PhEnotypic Characteristics, coMorBidities and response to thErapeutic inteRventions associated with non-type 2 asthma (EMBER)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50752
• EU PAS number:
  EUPAS43785
• Study ID:
  50752
• Official title and acronym:
  PhEnotypic Characteristics, coMorBidities and response to thErapeutic inteRventions associated with non-type 2 asthma (EMBER)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Australia

  Bulgaria

  Canada

  Colombia

  Denmark

  Greece

  India

  Ireland

  Italy

  Japan

  Korea, Republic of

  Kuwait

  Mexico

  Portugal

  Saudi Arabia

  Spain

  Taiwan

  United Arab Emirates

  United Kingdom

  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Optimum Patient Care (OPC)

United Kingdom

Networks

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 01/06/2021

Study start date

Planned: 01/06/2021

Data analysis start date

Planned: 01/11/2021

Date of final study report

Planned: 28/02/2023

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, OPC Global

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable